Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, established in 1907, is a leading Indian multinational pharmaceutical company headquartered in Vadodara, Gujarat. The company specializes in the development, manufacturing, marketing, and sale of pharmaceutical products, including active pharmaceutical ingredients (APIs) and finished dosage formulations. Alembic's product portfolio spans various therapeutic areas such as cardiology, dermatology, diabetes, ophthalmology, and infectious diseases. In fiscal year 2025, the company reported a revenue of ₹6,672 crore (approximately $797.4 million), marking a 7.1% increase from the previous year. The net income for the same period was ₹583.42 crore (approximately $70.5 million), reflecting a 5.3% decrease compared to the prior year. As of 2025, Alembic Pharmaceuticals employed 16,571 individuals. The company's stock is listed on the Bombay Stock Exchange (BSE) under the ticker symbol 533573 and on the National Stock Exchange of India (NSE) under APLLTD.

Alembic Pharmaceuticals operates multiple manufacturing facilities across India, including locations in Gujarat (Panelav and Karakhadi), Sikkim, and Pithampur. These facilities are equipped to produce a wide range of pharmaceutical products, including oral solids, injectables, and ophthalmic formulations. The company's manufacturing plants adhere to current Good Manufacturing Practice (cGMP) standards and have received approvals from various international regulatory agencies, ensuring the production of high-quality pharmaceutical products.

The leadership team at Alembic Pharmaceuticals is headed by Chairman and CEO Chirayu Ramanbhai Amin. Pranav Chirayu Amin serves as the Managing Director, while Shaunak Chirayu Amin also holds the position of Managing Director. Raj Kumar Baheti is the Chief Financial Officer and Director of Finance. This executive team is responsible for steering the company's strategic direction and overseeing its operations in the pharmaceutical industry.

Alembic Pharmaceuticals has established a significant presence in regulated markets, particularly in the United States. Between 2024 and 2025, the company secured multiple final and tentative approvals from the U.S. Food and Drug Administration (FDA) for generic medicines. Notably, in December 2024, Alembic received tentative approval for Olopatadine Hydrochloride Ophthalmic Solution 0.7%, a generic version of Pataday Once Daily Relief. In May 2025, the company obtained final approval for Rivaroxaban tablets in various strengths, therapeutically equivalent to Xarelto. Additionally, in June 2025, Alembic received final approval for Doxorubicin Hydrochloride Liposome Injection, a generic version of Doxil, indicated for certain cancers. These approvals underscore Alembic's commitment to expanding its footprint in the U.S. market. The company's products are also available in other regulated markets, including the European Union, the United Kingdom, Australia, and Japan, where they comply with respective regulatory standards.

Alembic Pharmaceuticals has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The company's adherence to World Health Organization (WHO) prequalification standards has facilitated access to these regions, enabling the supply of quality-assured pharmaceutical products. This commitment to international standards has bolstered Alembic's reputation and market share in these emerging markets.

Alembic Pharmaceuticals has adopted a diversified geographic strategy to mitigate concentration risk and capitalize on growth opportunities across various regions. The company's operations span domestic and international markets, with a significant focus on regulated markets such as the United States and the European Union. Simultaneously, Alembic has made strategic inroads into emerging markets, leveraging WHO prequalification to enhance its global footprint. This balanced approach reflects the company's strategic direction to achieve sustainable growth and market diversification.

Alembic Pharmaceuticals has a robust relationship with the U.S. Food and Drug Administration (FDA), evidenced by multiple approvals for its Abbreviated New Drug Applications (ANDAs). Between 2024 and 2025, the company received approvals for several generic medicines, including Olopatadine Hydrochloride Ophthalmic Solution 0.7%, Rivaroxaban tablets, Doxorubicin Hydrochloride Liposome Injection, and Tretinoin Cream USP 0.025%. These approvals highlight Alembic's commitment to meeting FDA standards and expanding its product offerings in the U.S. market. The company's facilities are registered with the FDA, and its products are subject to regular inspections to ensure compliance with U.S. regulatory requirements.

Alembic Pharmaceuticals' manufacturing facilities adhere to Good Manufacturing Practice (GMP) standards set by the World Health Organization (WHO) and the European Union (EU). The company's commitment to these international standards ensures the production of high-quality pharmaceutical products that meet global regulatory requirements. Alembic's compliance with WHO and EU GMP standards has facilitated its entry into various international markets, reinforcing its reputation as a reliable supplier of pharmaceutical products.

In India, Alembic Pharmaceuticals operates under the regulatory framework established by the Central Drugs Standard Control Organisation (CDSCO) and respective state drug controllers. The company's manufacturing facilities are licensed by the CDSCO, ensuring compliance with national standards for pharmaceutical production. Alembic also obtains necessary export No Objection Certificates (NOCs) from the Directorate General of Foreign Trade (DGFT) for international shipments, facilitating its global trade operations.

As of March 2026, there have been no publicly reported Form 483 observations, warning letters, or import alerts issued by the U.S. Food and Drug Administration (FDA) concerning Alembic Pharmaceuticals. The company's facilities have maintained compliance with FDA regulations, reflecting its commitment to quality and regulatory adherence. Alembic continues to monitor and address any regulatory developments to uphold its standing in the pharmaceutical industry.

Alembic Pharmaceuticals operates in a competitive landscape with several key players in the pharmaceutical industry. In the cardiovascular segment, Alembic's top products include Celecoxib, Losartan, and Telmisartan, with market shares of 9.1%, 3.7%, and 0.1%, respectively. In the analgesics and antipyretics category, Alembic's top product is Valsartan, holding a 5.3% market share. In the antibiotics segment, Azithromycin is Alembic's leading product with a 4.7% market share. These figures indicate Alembic's competitive positioning within these therapeutic areas.

Alembic Pharmaceuticals distinguishes itself through its vertically integrated operations, encompassing research and development, manufacturing, and marketing of pharmaceutical products. The company's adherence to international quality standards, including WHO and EU GMP certifications, ensures the production of high-quality products. Alembic's diverse therapeutic portfolio, spanning areas such as cardiology, dermatology, and infectious diseases, enables it to address a wide range of medical needs. Additionally, the company's strategic focus on both regulated and emerging markets enhances its global presence and growth prospects.

Alembic Pharmaceuticals has strategically positioned itself as a comprehensive pharmaceutical company, focusing on the development and marketing of generic formulations across various therapeutic areas. The company's recent approvals from the U.S. FDA for generic medicines in oncology, cardiovascular diseases, dermatology, and ophthalmology reflect its commitment to expanding its product portfolio. Looking ahead, Alembic aims to strengthen its presence in both regulated and emerging markets, leveraging its manufacturing capabilities and regulatory compliance to drive growth. The company's strategic direction emphasizes innovation, quality, and global expansion to maintain a competitive edge in the pharmaceutical industry.

Alembic Pharmaceuticals has demonstrated a strong track record in the pharmaceutical industry, with a total export value of $127.6 million USD and 3,520 shipments across 37 products in 16 therapeutic categories. The company's top five products—Celecoxib, Losartan, Telmisartan, Valsartan, and Azithromycin—account for 41.9% of its export portfolio, indicating a diversified product range. Alembic's adherence to international quality standards and regulatory compliance further underscores its reliability as a supplier. The company's consistent export